ImmunoPrecise Antibodies Ltd. (TSX-V:IPA) (OTCQB:IPATF) CEO Dr Jennifer Bath tells Proactive the technology platform company reported revenue increases by 39%, to $3.8 million in its first quarter financials, while the company initiates its pre-clinical coronavirus vaccine study. Bath says new client wins are driving growth, and the group hopes to report initial vaccine results, in partnership with Netherlands-based LiteVax, by November of this year.
viewImmunoPrecise Antibodies Ltd
ImmunoPrecise Antibodies reveals 39% growth in 1Q revenue, initiates pre-clinical coronavirus vaccine study
Quick facts: ImmunoPrecise Antibodies Ltd
Price: 19 CAD
TSX-V:IPA
Market: TSX-V
Market Cap: $318.47 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of ImmunoPrecise Antibodies Ltd named herein, including the promotion by the Company of ImmunoPrecise Antibodies Ltd in any Content on the Site,...
FOR OUR FULL DISCLAIMER CLICK HEREMost read
Industry & services
New space ETF on the horizon lifts shares in Virgin Galactic, Maxar and SRAC
5 days, 1 hour ago
Health
Tiziana Life Sciences hires scientist with track record of successfully...
6 days, 8 hours ago
